Macular degeneration is very common and affects an estimated 19.8 million people in the United States. Approximately one in 10 Americans age 50 and older have an early form of the disease and as many ...

Breakthroughs in age-related macular degeneration (AMD) treatments have revolutionized the management of this progressive and potentially devastating eye disease. These include treatments such as ...

More information: Jimmy S. Chen et al, High Density Lipoproteins Associate with Age-Related Macular Degeneration in the All of Us Research Program, Ophthalmology (2025). DOI: 10.1016/j.ophtha.2024 ...

Age-related macular degeneration (AMD) is the leading cause of vision loss for people over 65. We have excellent treatments for the wet form of AMD. But until recently, we haven’t had any ...

More information: Bryan R. Gorman et al, Genome-wide association analyses identify distinct genetic architectures for age-related macular degeneration across ancestries, Nature Genetics (2024 ...

Age-related macular degeneration (AMD), which affects about 200 million people worldwide and can result in legal blindness, impairs an area of the eye (retina) used for reading, driving and many ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration, a leading cause of blindness in adults over 55. Developed by LumiThera Inc., the device showed ...

The Brooklyn-based startup is specifically targeting people with macular degeneration. The degenerative eye disease affects roughly 13% of U.S. residents aged 40 and up, according to figures from ...

SolidddVision smartglasses, the first true vision correction for people living with vision loss due to macular degeneration, is making its debut at CES 2025. Macular degeneration is an eye disease ...

Figure. Schematic illustration of the traditional and new functions of macula densa (MD)–derived prostaglandin E2 (PGE2). The sensing of reduced tubular (NaCl) via the furosemide-sensitive Na:2Cl:K ...